Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 250

1.

Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.

Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL.

Br J Cancer. 2011 Jan 4;104(1):120-7. doi: 10.1038/sj.bjc.6606021. Epub 2010 Dec 7.

PMID:
21139586
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Immunohistochemical categorisation of ductal carcinoma in situ of the breast.

Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ.

Br J Cancer. 2008 Jan 15;98(1):137-42. Epub 2007 Nov 27.

PMID:
18043578
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.

Steinman S, Wang J, Bourne P, Yang Q, Tang P.

Ann Clin Lab Sci. 2007 Spring;37(2):127-34.

PMID:
17522367
[PubMed - indexed for MEDLINE]
4.

Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.

Bryan BB, Schnitt SJ, Collins LC.

Mod Pathol. 2006 May;19(5):617-21.

PMID:
16528377
[PubMed - indexed for MEDLINE]
Free Article
5.

Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.

Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC.

Breast Cancer Res. 2008;10(4):R67. doi: 10.1186/bcr2128. Epub 2008 Aug 5.

PMID:
18681955
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.

Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):183-9. doi: 10.1016/j.clon.2011.09.008. Epub 2011 Sep 29.

PMID:
21958729
[PubMed - indexed for MEDLINE]
7.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

PMID:
18316557
[PubMed - indexed for MEDLINE]
Free Article
8.

p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.

Megha T, Ferrari F, Benvenuto A, Bellan C, Lalinga AV, Lazzi S, Bartolommei S, Cevenini G, Leoncini L, Tosi P.

J Clin Pathol. 2002 Jun;55(6):461-6.

PMID:
12037031
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.

Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu S.

Ann Clin Lab Sci. 2006 Spring;36(2):137-43.

PMID:
16682508
[PubMed - indexed for MEDLINE]
10.
11.

Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.

Ko E, Park SE, Cho EY, Kim Y, Hwang JA, Lee YS, Nam SJ, Bang S, Park J, Kim DH.

Breast Cancer Res. 2010;12(6):R100. doi: 10.1186/bcr2783. Epub 2010 Nov 23.

PMID:
21092257
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].

Liu H, Fan QH, Zhang ZH, Li X, Yu HP, Liu GZ, Meng FQ.

Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8. Chinese.

PMID:
19489221
[PubMed - indexed for MEDLINE]
13.

Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.

PMID:
19723150
[PubMed - indexed for MEDLINE]
14.

Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.

Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirström K, Bergh J, Wärnberg F.

Eur J Cancer. 2014 Feb;50(3):517-24. doi: 10.1016/j.ejca.2013.10.020. Epub 2013 Nov 22.

PMID:
24275214
[PubMed - indexed for MEDLINE]
15.

Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.

Zhou W, Jirström K, Amini RM, Fjällskog ML, Sollie T, Lindman H, Sørlie T, Blomqvist C, Wärnberg F.

BMC Cancer. 2013 Oct 30;13:512. doi: 10.1186/1471-2407-13-512.

PMID:
24171825
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.

Baqai T, Shousha S.

Histopathology. 2003 May;42(5):440-7.

PMID:
12713620
[PubMed - indexed for MEDLINE]
17.

Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.

Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, Shao ZM.

Ann Surg Oncol. 2011 May;18(5):1342-8. doi: 10.1245/s10434-010-1407-3. Epub 2010 Nov 2.

PMID:
21042943
[PubMed - indexed for MEDLINE]
18.

Molecular subtyping of male breast cancer by immunohistochemistry.

Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ.

Mod Pathol. 2012 Mar;25(3):398-404. doi: 10.1038/modpathol.2011.174. Epub 2011 Nov 4.

PMID:
22056953
[PubMed - indexed for MEDLINE]
Free Article
19.

Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.

Nassar A, Sussman ZM, Lawson D, Cohen C.

Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.

PMID:
22882580
[PubMed - indexed for MEDLINE]
20.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

PMID:
18045647
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk